Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPRES Extension: Imatinib in Severe Pulmonary Arterial Hypertension
NCT01117987Phase 3Terminated
- Sponsor
- Novartis
- Start
- Apr 2010
- Primary completion
- Apr 2014
- Modality
- Small Molecules
- Countries
- 13
01
Overview
A Phase 3 trial of imatinib in pulmonary arterial hypertension (PAH), sponsored by Novartis. Started Apr 2010; status: terminated.
02
Drugs
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT01117987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01117987.